ME01507B - IMIDAZOTRIAZINI I IMIDAZOPIRIMIDINI KAO INHIBITORI KINAZE - Google Patents

Claims (66)

1. Compound of formula 1: or its pharmaceutically acceptable salt or its prodrug, characterized in that: A is N or CR3; and (a) wherein, when A is N; Cy1 is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 -W-X-Y-Z; Cy2 is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, each optionally substituted with 1, 2, 3, 4, or 5 -W'-X'-Y'-Z'; L1 is CH2, CH2CH2, cycloalkylene, O or S L2 is (CR7R8)r, (CR7R8)s-(cycloalkylene)-(CR7R8)t, (CR7R8)s-(arylene)-(CR7R8)t, (CR7R8)s -(heterocycloalkylene)-(CR7R8)t, (CR7R8)s-(heteroarylene)-(CR7R8)t, (CR7R8)sO(CR7R8)t, (CR7R8)sS(CR7R8)t, (CR7R8)sC(O )(CR7R8)t, (CR7R8)sC(O)NR9(CR7R8)t, (CR7R8)sC(O)O(CR7R8)t, (CR7R8)sOC(O)(CR7R8)t, (CR7R8)sOC(O )NR9(CR7R8)t, (CR7R8)sNR9(CR7R8)t, (CR7R8)sNR9C(O)NR9(CR7R8)t, (CR7R8)sS(O) (CR7R8)t, (CR7R8)sS(O)NR7( CR8R9)t, (CR7R8)sS(O)2(CR7R8)t, or (CR7R8)sS(O)2NR9(CR7R8)t, wherein said cycloalkylene, arylene, heterocycloalkylene, or heteroarylene is optionally substituted with 1, 2 or 3 substituents independently selected from Cy4, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halosulfanyl, CN, NO2, N3, ORa1, SRa1, C(O)Rb1, C(O )NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, C(=NRg)NRc1Rd1, NRc1C( =NRg)NRc1Rd1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, NRc1S(O )2Rb1, and S(O)2NRc1Rd1; R 1 is H or ⎯W"-X"-Y"-Z"; R2 is H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, ORA, SRA, C(O)RB, C(O)NRCRD, C(O) ORA, OC(O)RB, OC(O)NRCRD, NRCRD, NRCC(O)RB, NRCC(O)NRCRD, NRCC(O)ORA, S(O)RB, S(O)NRCRD, S(O) 2RB, NRCS(O)2RB or S(O)2NRCRD; R3 is H, cycloalkyl, aryl, heterocycloalkyl, heteroaryl, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, ORA, SRA, C(O)RB, C( O)NRCRD, C(O)ORA, OC(O)RB, OC(O)NRCRD, NRCRD, NRCC(O)RB, NRCC(O)NRCRD, NRCC(O)ORA, S(O)RB, S( O)NRCRD, S(O)2RB, NRCS(O)2RB and S(O)2NRCRD; wherein said cycloalkyl, aryl, heterocycloalkyl, heteroaryl or C1-6 alkyl is optionally substituted with 1,2 or 3 substituents independently selected from Cy5, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl , halosulfanyl, CN, NO2, N3, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1 , NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, C(=NRg)NRc1Rd1, NRc1C(=NRg)NRc1Rd1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1 , S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, NRc1S(O)2Rb1 and S(O)2NRc1Rd1; or R 2 and ⎯L 2 -Cy 2 are linked together to form a group of the formula: wherein ring B is a fused aryl or fused heteroaryl ring, each optionally substituted with 1, 2 or 3 -W'-X'-Y'-Z'; R 4 is independently selected from H, halo, OH, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, alkoxyalkyl, cyanoalkyl, heterocycloalkyl, cycloalkyl, C 1-6 haloalkyl, CN, and NO 2 ; R 7 and R 8 are independently selected from H, halo, OH, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 haloalkyl, CN and NO 2 ; or R7 and R8 together with the C atom to which they are attached form a 3, 4, 5, 6 or 7-membered cycloalkyl or heterocycloalkyl ring, each optionally substituted with 1, 2 or 3 substituents independently selected from halo, OH, C1-6 alkyl , C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, CN and NO2; R 9 is H, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl; W, W' and W" are independently absent or independently selected from C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, O, S, NRh, CO, COO, CONRh, SO, SO2, SONRh and NRhCONRi, at wherein each of C1-6 alkylene, C2-6 alkenylene and C2-6 alkynylene is optionally substituted with 1, 2 or 3 substituents selected from halo, C1-6 alkyl, C1-6 haloalkyl, OH, C1-6 alkoxy, C1- 6 haloalkoxy, amine, C1-6 alkylamine and C2-8 dialkylamine; X, X' and X" are independently absent or independently selected from C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, arylene, cycloalkylene, heteroarylene and heterocycloalkylene, wherein each of C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, arylene, cycloalkylene, heteroarylene and heterocycloalkylene is optionally substituted with 1, 2 or 3 substituents independently selected from halo, CN, NO2, OH, C1 -6 Alkyl, C1-6 Haloalkyl, C2-8 Alkoxyalkyl, C1-6 Alkoxy, C1-6 Haloalkoxy, C2-8 Alkoxyalkoxy, Cycloalkyl, Heterocycloalkyl, C(O)ORj, C(O)NRhRi, Amine, C1-6 alkylamines and C2-8 dialkylamines; Y, Y' and Y" are independently absent or independently selected from C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, O, S, NRh, CO, COO, CONRh, SO, SO2, SONRh, and NRhCONRi, wherein each of C1-6 alkylene, C2-6 alkenylene and C2-6 alkynylene is optionally substituted with 1, 2 or 3 substituents independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, OH, C1-6 alkoxy, C1-6 haloalkoxy, amine, C1-6 alkylamine and C2-8 dialkylamine; Z, Z' and Z" are independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halosulfanyl, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O) Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(=NR9)NRc2Rd2, NRc2C(=NR9)NRc2Rd2, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P(O) ORe2ORf2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, NRc2S(O)2Rb2, S(O)2NRc2Rd2, aryl, cycloalkyl, heteroaryl and heterocycloalkyl, where C1-6 *alkyl, C2 -6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1 -6 haloalkyl, halosulfanyl, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C( O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(=NRg)NRc2Rd2, NRc2C(=NRg)NRc2Rd2, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P( O)ORe2ORf2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, NRc2S(O)2Rb2 and S(O)2NRc2Rd2; wherein two adjacent ⎯W-X-Y-Z, together with the atoms to which they are attached, optionally form a 4-20 membered fused cycloalkyl ring or a 4-20 membered fused heterocycloalkyl ring, each optionally substituted with 1, 2 or 3 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halosulfanyl, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC( O)Rb3, OC(O)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)NRc3Rd3, NRc3C(O)ORa3, C(=NRg)NRc3Rd3, NRc3C(=NRg)NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, NRc3S(O)2Rb3, S(O)2NRc3Rd3, aryl, cycloalkyl, heteroaryl and heterocycloalkyl; wherein two adjacent ⎯W'-X'-Y'-Z', together with the atoms to which they are attached, optionally form a fused 4-20 membered cycloalkyl ring or a fused 4-20 membered heterocycloalkyl ring, each optionally substituted with 1 , 2 or 3 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halosulfanyl, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O) NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, NRc3Rd3 , NRc3C(O)Rb3, NRc3C(O)NRc3Rd3, NRc3C(O)ORa3, C(=NRg)NRc3Rd3, NRc3C(= NRg)NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, NRc3S(O)2Rb3, S(O)2NRc3Rd3, aryl, cycloalkyl, heteroaryl and heterocycloalkyl; Cy4 and Cy5 are independently selected from aryl, cycloalkyl, heteroaryl and heterocycloalkyl, each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1 -6 haloalkyl, halosulfanyl, CN, NO2, N3, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C( O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRg)NRc4Rd4, NRc4C(=NRg)NRc4Rd4, P(Rf4)2, P(OR4)2, P(O)Re4Rf4, P( O)ORe4ORf4, S(O)b4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4 and S(O)2NRc4Rd4; RA is H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl wherein C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl optionally substituted with 1, 2 or 3 substituents independently selected from OH, CN, amino, halo and C1-4 alkyl; RB is H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl wherein said C1-4 alkyl, C2-4 alkenyl, or C2-4 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl optionally substituted with 1, 2 or 3 substituents independently selected from OH, CN, amino, halo and C1-4 alkyl; RC and RD are independently selected from H, C1-4 alkyl, C2-4 alkenyl, or C2-4 alkynyl, wherein said C1-4 alkyl, C2-4 alkenyl, or C2-4 alkynyl is optionally substituted with 1, 2 or 3 substituents independently selected from OH, CN, amino, halo and C1-4 alkyl; or RC and RD together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2 or 3 substituents independently selected from OH, CN, amino, halo and C1-4 alkyl; Ra, Ra1, Ra2, Ra3, and Ra4 are independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl and C1-6 haloalkoxy; Rb, Rb1, Rb2, Rb3 and Rb4 are independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl. , wherein said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alknyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2 or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl and C1-6 haloalkoxy; Rc and Rd are independently selected from H, C1-10 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl, wherein said C1 -10 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl optionally substituted with 1, 2 or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl and C1-6 haloalkyl; or Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2 or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl and C1-6 haloalkoxy; Rc1 and Rd1 are independently selected from H, C1-10 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl, wherein said C1 -10 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl optionally substituted with 1, 2 or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, and C 1-6 haloalkoxy; or Rc1 and Rd1 together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2 or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl and C1-6 haloalkoxy; Rc2 and Rd2 are independently selected from H, C1-10 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylcycloalkyl, arylheterocycloalkyl, arylheteroaryl , biaryl, heteroarylcycloalkyl, heteroarylheterocycloalkyl, heteroarylaryl and biheteroaryl, wherein said C1-10 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl , arylcycloalkyl, arylheterocycloalkyl, arylheteroaryl, biaryl, heteroarylcycloalkyl, heteroarylheterocycloalkyl, heteroarylaryl and biheteroaryl each optionally substituted with 1, 2 or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, hydroxyalkyl, cyanoalkyl, aryl, heteroaryl, C(O)ORa 4 , C(O)Rb 4 , S(O) 2 Rb 3 , alkoxyalkyl and alkoxyaloxy; or Rc2 or Rd2 together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2 or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, hydroxyalkyl, cyanoalkyl, aryl, heteroaryl, C(O)ORa4, C(O)Rb4, S(O)2Rb3, alkoxyalkyl and Alkoxyalkoxy; Rc3 and Rd3 are independently selected from H, C1-10 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl, wherein said C1 -10 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl optionally substituted with 1, 2 or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl and C1-6 haloalkoxy; or Rc3 and Rd3 together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2 or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl and C1-6 haloalkoxy; Rc4 and Rd4 are independently selected from H, C1-10 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl, wherein said C1 -10 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl optionally substituted with 1, 2 or 3 substituents independently selected from OH, CN, amino, halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, and C 1-6 haloalkoxy; or Rc4 and Rd4 together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2 or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl and C1-6 haloalkoxy; Re, Re1, Re2 and Re4 are independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, (C1-6 alkoxy)-C1-6 alkyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl , heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocycloalkylalkyl; Rf, Rf1, Rf2 and Rf4 are independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl; Rg is H, CN and NO2; Rh and R 1 are independently selected from H and C 1-6 alkyl; Rj is H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl; r is 0, 1, 2, 3, 4, 5 or 6; s is 0, 1, 2, 3 or 4; and t is 0, 1, 2, 3 or 4; and (b) wherein, when A is CR3: L' is cycloalkylene, O or S; and all other variables are defined as under (a) 2. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that A is N. 3. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that A is CR3. 4. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that A is CH. 5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that Cy1 is aryl or heteroaryl, each optionally substituted with 1, 2, 3, 4 or 5 -W-X-Y-Z. 6. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that Cy1 is aryl optionally substituted with 1, 2, 3, 4 or 5 -W-X-Y-Z. 7. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that Cy1 is heteroaryl optionally substituted with 1, 2, 3, 4 or 5 -W-X-Y-Z. 8. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that Cy1 is quinonelinyl optionally substituted with 1, 2, 3, 4 or 5 -W-X-Y-Z. 9. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that Cy1 is quinolinyl. 10. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that Cy2 is aryl or heteroaryl, each optionally substituted with 1, 2, 3, 4 or 5 -W'-X'-Y'-Z'. 11. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that Cy2 is aryl or heteroaryl, each optionally substituted with 1, 2, 3, 4 or 5 -W'-X'-Y'-Z', wherein at least one of the above -W'-X'-Y'-Z' is C(O)NRc2Rd2. 12. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that Cy2 is aryl optionally substituted with 1, 2, 3, 4 or 5 -W'-X'-Y'-Z'. 13. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that Cy2 is heteroaryl optionally substituted with 1, 2, 3, 4 or 5 -W'-X'-Y'-Z'. 14. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that L1 is O or S. 15. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that L1 is CH2 or CH2CH2 or cycloalkylene. 16. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that L1 is CH2 or cyclopropylene. 17. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that L1 is cycloalkylene. 18. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that L1 is cyclopropylene. 19. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that L2 is (CR7R8)r. 20. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that L2 is (CR7R8)r and r is 0. 21. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that L2 is (CR7R8)r, (CR7R8)s-(cycloalkylene)-(CR7R8)t, (CR7R8)s-(arylene)-(CR7R8)t, (CR7R8)s-(heterocycloalkylene)-(CR7R8)t or (CR7R8)s-(heteroarylene)-(CR7R8)t, wherein said cycloalkylene, arylene, heterocycloalkylene or heteroarylene is optionally substituted with 1, 2 or 3 substituents independently selected from Cy4, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halosulfanyl, CN, NO2, N3, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C( O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, C(=NRg)NRc1Rd1, NRc1C(=NRg)NRc1Rd1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORelORfi, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, NRc1S(O)2Rb1, and S (O)2NRc1Rd1. 22. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that L2 is (CR7R8)r, (CR7R8)s-(cycloalkylene)-(CR7R8)t or (CR7R8)-(arylene)-(CR7R8)t, where is said cycloalkylene or arylene optionally substituted with 1, 2 or 3 substituents independently selected from Cy4, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halosulfanyl, CN, NO2, N3, ORa1 , SRa1, C(O)Rb1, C(O)NRclRad1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O )ORa1, C(=NRg)NRc1Rd1, NRc1C(=NRg)NRc1Rd1, P(Rf1)2, P(ORe1)2,P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rb1, S(O )NRc1Rd1, S(O)2Rb1, NRc1S(O)2Rb1 and S(O)2NRc1Rd1. 23. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that L2 is (CR7R8)s-(cycloalkylene)-(CR7R8)t or (CR7R8)s-(arylene)-(CR7R8)t, where said cycloalkylene or arylene optionally substituted with 1, 2 or 3 substituents independently selected from Cy4, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halosulfanyl, CN, NO2, N3, ORa1, SRa1, C (O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, C (=NRg)NRc1Rd1, NRc1C(=NRg)NRc1Rd1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1. P(O)ORe1ORf1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, NRc1S(O)2 Rb1 and S(O)2NRc1Rd1. 24. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that L2 is cycloalkylene or arylene. 25. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that L2 is arylene. 26. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that Cy2 is aryl optionally substituted with 1, 2, 3, 4 or 5 -W'-X'-Y'-Z'. 27. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that Cy2 is heteroaryl optionally substituted with 1, 2, 3, 4 or 5 -W'-X'-Y'-Z'. 28. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that Cy2 is cycloalkyl optionally substituted with 1, 2, 3, 4 or 5 -W'-X'-Y'-Z'. 29. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that Cy2 is heterocycloalkyl optionally substituted with 1, 2, 3, 4 or 5 -W'-X'-Y'-Z'. 30. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that R1 is H. 31. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that R2 is H. 32. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that R3 is H. 33. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that R4 is H. 34. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that R7 is H. 35. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that R8 is H. 36. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that R9 is H. 37. In accordance with claim 1, pharmaceutical acceptable sol, indicated by -W-X-Y-Z is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halosulfanil, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O) ORa2, C(=NRg)NRc2Rd2, NRc2C(=NRg)NRc2Rd2, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P(O)ORe2ORf12, S(O)Rb2, S(O) NRc2Rd2, S(O)2Rb2, NRc2S(O)2Rb2, S(O)2NRc2Rd2, aryl, cycloalkyl, heteroaryl and heterocycloalkyl, pri čemu je navedeni C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl , heteroaryl i heterocikloalkyl izborno zamijenj s 1, 2, 3, 4 ili 5 substituenta independently selected od halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halosulfanyl, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C( O)ORa2, C(=NRg)NRc2Rd2, NRc2C(=NRg)NRc2Rd2, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P(O)ORe2ORf2, S(O)Rb2, S( O)NRc2Rd2, S(O)2Rb2,NRc2S(O)2Rb2 to S(O)2NRc2Rd2. 38. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that -W-X-Y-Z is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halosulfanyl, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O) ORa2, C(=NRg)NRc2Rd2, NRc2C(=NRg)NRc2Rd2, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P(O)ORe2ORf2, S(O)Rb2, S(O) NRc2Rd2, S(O)2Rb2, NRc2S(O)2Rb2 or S(O)2NRc2Rd2. 39. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that -W-X-Y-Z is halo, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, N3 or ORa2. 40. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that –W-X-Y-Z is ORa2. 41. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that -W-X-Y-Z is methoxy. 42.Spoj prema svettiti 1 ili nejava pharmaceutis adgilibatana sol, nacetani time da – W'-X'-Y'-Z' jest halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halosulfanil, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(=NRg)NRc2Rd2, NRc2C(=NRg)NRc2Rd2, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P(O)ORe2ORf2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, NRc2S(O)2Rb2, S(O)2NRc2Rd2, aryl, cycloalkyl, heteroaryl to heterocycloalkyl, pri čemu je navedeni C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl i heterocycloalkyl izborno zamijenn sa 1, 2, 3, 4 ili 5 substituenta independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynila, C1-6 haloalkyl, halosulfanyl, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O) Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(=NRg)NRc2Rd2, NRc2C(=NRg)NRc2Rd2, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P(O) ORe2ORf2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, NRc2S(O)2Rb2 to S(O)2NRc2Rd2. 43. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that –W'-X'-Y'-Z' is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halosulfanyl, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(=NRg)NRc2Rd2, NRc2C(=NRg)NRc2Rd2, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P(O)ORe2ORf2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, NRc2S(O)2Rb2 or S(O)2NRc2Rd2. 44. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that –W'-X'-Y'-Z'is halo, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, N3, ORa2 or C( O)NRc2Rd2 45. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that -W'-X'-Y'-Z' is halo, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, N3 or ORa2. 46. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that -W'-X'-Y'-Z' is halo or C(O)NRc2Rd2. 47. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that they have the formula IIa or IIb: 48. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that they have the formula III: 49. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that they have the formula VIII: 50.Spoj according to claim 1, selected from: 2-(4-fluorophenyl)-7-(4-methoxybenzyl)imidazo[1,2-b] [1,2,4]triazine; 2-(4-fluorophenyl)-7-[1-(4-methoxyphenyl)cyclopropyl]imidazo[1,2-b]-[1,2,4]-triazine; 6-(1-(2-(4-fluorophenyl)imidazo[1,2-b][1,2,4]triazin-7-yl)cyclopropyl)quinoline; 6-(4-fluorophenyl)-3-(4-methoxybenzyl)imidazo[1,2-a]pyrimidine; 6-(4-fluorophenyl)-3-(1-(4-methoxyphenyl)cyclopropyl)imidazo[1,2-a]pyrimidine; 6-(1-(6-(4-fluorophenyl)imidazo[1,2-a]pyrimidin-3-yl)cyclopropyl)quinoline; 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; 2-(4-bromo-3-fluorophenyl)-7-[(4-methoxyphenyl)thio]imidazo[1,2-b][1,2,4]triazine; 2-fluoro-4-(3-[(4-methoxyphenyl)thio]imidazo[1,2-a]pyrimidin-6-yl)-N-methylbenzamide; 2-chloro-4-3-[(4-methoxyphenyl)thio]imidazo[1,2-a]pyrimidin-6-yl-N-methylbenzamide; 2-Fluoro-N-methyl-4-[3-(quinolin-6-1thio)imidazo[1,2-a]pyrimidin-6-yl]benzamide; 2-chloro-N-methyl-4-[3-(quinolin-6-ylthio)imidazo[1,2-a]pyrimidin-6-yl]benzamide; methyl-2-fluoro-4-[7-(quinolin-6-ylthio)imidazo[1,2-b][1,2,4]triazin-2-yl]benzoate; 2-(4-bromo-3-fluorophenyl)-7-(4-methoxyphenoxy)imidazo[1,2-b][1,2,4]triazine; 3-(4-Methoxyphenoxy)-6-(4-methyl-1H-pyrazol-1-yl)imidazo[1,2-a]pyrimidine; 6-(4-bromophenyl)-3-(4-methoxyphenoxy)imidazo[1,2-a]pyrimidine; 2-chloro-N-methyl-4-[3-(quinolin-6-yloxy)imidazo[1,2-a]pyrimidin-6-yl]benzamide; 2-fluoro-N-methyl-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; 6-(4-bromophenyl)-3-[(4-methoxyphenyl)thio]imidazo[1,2-a]pyrimidine; 2-(4-fluorophenyl)-7-[(4-methoxyphenyl)thio]imidazo[1,2-b][1,2,4]triazine; 6-(1-{6-[3-fluoro-4-(1-methyl-2-oxo-2-pyrrolidin-1-ylethoxy)phenyl]imidazo[1,2-a]pyrimidin-3-yl}cyclopropyl) quinoline; 6-{1-[6-(1H-pyrazol-1-yl)imidazo[1,2-a]pyrimidin-3-yl]cyclopropyl}quinoline; 6-1-[6-(4-methyl-1H-pyrazol-1-yl)imidazo[1,2-a]pyrimidin-3-yl]cyclopropyl}quinoline; N,N-dimethyl-1-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]-1H-pyrazole-4-carboxamide; N-[1-(4-methyl-1,3-thiazol-2-yl)ethyl]-1-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl ]-1H-pyrazole-4-carboxamide; N-cyclohexyl-3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidine-6-carboxamide; 3-(1-quinolin-6-ylcyclopropyl)-N-(tetrahydrofuran-2-ylmethyl)imidazo[1,2-a]pyrimidine-6-carboxamide; N-cyclobutyl-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; 6-(1-{16-[4-(azetidin-1-ylcarbonyl)phenyl]imidazo[1,2-a]pyrimidin-3-yl}cyclopropyl)quinoline; N,N-dimethyl-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; 4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]-N-(tetrahydrofuran-2-ylmethyl)benzamide; N-(1-benzylpyrrolidin-3-yl)-N-methyl-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; N-(1-pyridin-2-ylpiperidin-4-yl)-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; N-(1-pyridin-2-ylethyl)-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; 6-{1-[6-(4-[(3S)-3-fluoropyrrolidin-1-yl]carbonylphenyl)imidazo[1,2-a]pyrimidin-3-yl]cyclopropyl}quinoline; N-[1-(methoxymethyl)cyclobutyl]-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; N-(1-pyridin-2-ylpyrrolidin-3-yl)-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; 6-[1-(6-{4-[(3-pyridin-2-ylpyrrolidin-1-yl)carbonyl]phenyl}imidazo[1,2-a]pyrimidin-3-yl)cyclopropyl]quinoline; 6-{1-[6-(4-[(3S)-3-(pyridin-2-yloxy)pyrrolidin-1-yl]carbonylphenyl)imidazo[1,2-a]pyrimidin-3-yl]cyclopropyl}quinoline ; N-[2-(pyridin-2-yloxy)ethyl]-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; N-[1-methyl-2-(pyridin-2-yloxy)ethyl]-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; N-(2-phenoxyethyl)-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; N-(1S)-2,2-dimethyl-1-[(methylamino)carbonyl]propyl-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl] benzamide; N-(1S)-1-[(dimethylamino)carbonyl]-2,2-dimethylpropyl-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide ; N-[(1S)-1-(azetidin-1-ylcarbonyl)-2,2-dimethylpropyl]-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6- il]benzamide; N-cyclopropyl-3-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; N-(pyridin-2-ylmethyl)-3-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; N,N-dimethyl-3-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; N-methyl-3-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; N-[(1S)-1-methyl-2-(methylamino)-2-oxoethyl]-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl] benzamide; N-[(1R)-1-methyl-2-(methylamino)-2-oxoethyl]-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl] benzamide; (3R)-1-{4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzoyl}pyrrolidine-3-carbonitrile; methyl-4-{5-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]pyridin-2-yl}-piperazin-1-carboxylate; 6-[1-(6-{6-[4-(methylsulfonyl)piperazin-1-yl]pyridin-3-yl}imidazo[1,2-a]pyrimidin-3-yl)cyclopropyl]quinoline; N,N-dimethyl-4-{5-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]pyridin-2-yl}piperazine-1-carboxamide; N-(1S)-1-[(dimethylamino)carbonyl]-2-methylpropyl-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; N-1-[(dimethylamino)carbonyl]cyclobutyl-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; N-[(1S)-1-(azetidin-1-ylcarbonyl)-2,2-dimethylpropyl]-5-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6- 1]pyridine-2-carboxamide; N-(1S)-2,2-dimethyl-1-[(methylamino)carbonyl]propyl-5-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl] pyridine-2-carboxamide; N-(1S)-1-[(cyclopropylamino)carbonyl]-2,2-dimethylpropyl-5-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]pyridine -2-carboxamide; N-[(1S)-2-(dimethylamino)-1-methyl-2-oxoethyl]-5-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl] pyridine-2-carboxamide; N-[(1R)-2-(dimethylamino)-1-methyl-2-oxoethyl]-5-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl] pyridine-2-carboxamide; 6-(1-{6-[4-(2-oxo-2-pyrrolidin-1-ylethoxy)phenyl]imidazo[1,2-a]pyrimidin-3-yl}cyclopropyl)quinoline; 1-{4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]phenyl}cyclopropanecarbonitrile; N,N-dimethyl-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzenesulfonamide; methyl-2-fluoro-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzylcarbamate; N'-2-fluoro-4[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzyl-N,N-dimethylurea; (3R)-1-{2-fluoro-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzyl}pyrrolidin-3-ol; 6-(1-{6-[3-fluoro-4-(1H-pyrazol-1-ylmethyl)phenyl]imidazo[1,2-a]pyrimidin-3-yl}cyclopropyl)quinoline; 3-{2-fluoro-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzyl}-1,3-oxazolidin-2-one; 2-fluoro-N-methyl-4-[7-(quinoxalin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; 6-{1-[6-(4-chloro-1H-pyrazol-1-yl)imidazo[1,2-a]pyrimidin-3-yl]cyclopropyl}quinoline; 6-{1-[6-(2-methyl-1,3-thiazol-4-yl)imidazo[1,2-a]pyrimidin-3-yl]cyclopropyl}quinoline; 6-{1-[6-(1,3-thiazol-4-yl)imidazo[1,2-a]pyrimidin-3-yl]cyclopropyl}quinoline; 3-fluoro-N-methyl-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; (3S)-1-{3-fluoro-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzoyl}pyrrolidin-3-ol; 2,5-difluoro-N-methyl-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; 2,5-difluoro-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; N-cyclopropyl-2,5-difluoro-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; 2,5-difluoro-N-(trans-4-hydroxycyclohexyl)-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; 1-{2-fluoro-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]phenyl}pyrrolidin-2-one; 3-{2-fluoro-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]phenyl}-1,3-oxazolidin-2-one; ethyl-4-{4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]-1H-pyrazol-1-yl}piperidin-1-carboxylate; 2-(4-{2-fluoro-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]phenyl}-1H-pyrazol-1-yl)- N,N-dimethylacetamide; 5-{2-fluoro-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]phenyl}-N-methylpyridine-2-carboxamide; 5-{2-fluoro-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]phenyl}-N,N-dimethylpyridine-2-carboxamide; 6-(1-{6-[3-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl]imidazo[1,2-a]pyrimidin-3-yl}cyclopropyl)quinoline; 6-(1-{6-[1-(tetrahydrofuran-3-yl)-1H-pyrazol-4-yl]imidazo[1,2-a]pyrimidin-3-yl}cyclopropyl)quinoline; 6-(1-{6-[1-(1-benzylpyrrolidin-3-yl)-1H-pyrazol-4-yl]imidazo[1,2-a]pyrimidin-3-yl}cyclopropyl)quinoline; 6-{1-[6-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyrimidin-3-yl]cyclopropyl}quinoline; N,N-dimethyl-4-{4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]-1H-pyrazol-1-yl}piperidin-1-carboxamide; 4-{4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]-1H-pyrazol-1-yl}cyclohexanol; {4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]-1H-pyrazol-1-yl} acetonitrile; N-methyl-5-{4-[7-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-b][1,2,4]triazin-2-yl]phenyl}pyridine-2-carboxamide; 6-{1-[2-(4-pyrimidin-5-yl-phenyl)imidazo[1,2-b][1,2,4]triazin-7-yl]cyclopropyl}quinoline; 6-(1-{2-[4-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]imidazo[1,2-b][1,2,4]triazine-7 -yl}cyclopropyl)quinoline; 6-[1-(2-(4-[1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}imidazo[1,2-b][1,2,4]triazine -7-yl)cyclopropyl]quinoline;N,N-dimethyl-5-{4-[7-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-b][1,2,4]triazin-2 -yl]phenyl}pyridine-2-carboxamide;6-(1-{2-[4-(1H-imidazol-1-yl)phenyl]imidazo[1,2-b][1,2,4]triazin- 7-yl}cyclopropyl)-quinoline;2-fluoro-N-(trans-4-hydroxycyclohexyl)-4-[7-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-b][1,2, 4]triazin-2-yl]benzamide;N-cyclopropyl-2-fluoro-4-[7-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-b][1,2,4]triazin-2 -yl]benzamide 2-fluoro-N-methyl-4-[7-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; 2-fluoro-N-[1-(methoxymethyl)cyclopropyl]-4-[7-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-b][1,2,4]triazin-2-yl] benzamide; 2-fluoro-4-(7-(1-(quinolin-6-yl)cyclopropyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; 4-[7 -(1-quinolin-6-ylcyclopropyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-N-(tetrahydrofuran-2-ylmethyl)benzamide;N-(pyridin-2- ylmethyl)-4-[7-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; N-cyclopropyl-4-[7-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; N-cyclobutyl-4-[7-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; N-(1-pyridin-2-ylcyclopropyl)-4-[7-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; N-(2-hydroxy-1,1-dimethylethyl)-4-[7-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide ; N-[(1S)-1-benzyl-2-hydroxyethyl]-4-[7-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-b][1,2,4]triazin-2-yl ]benzamide; (3R)-1-{4-[7-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzoyl}pyrrolidin-3-ol; 4-(7-(1-(quinolin-6-yl)cyclopropyl)imidazo[1,2-b][1,2,4]triazin-2-yl)-N-(tetrahydro-2H-pyran-4- il)benzamide; N-cyclopropyl-N-methyl-4-[7-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; N-[1-(methoxymethyl)cyclopropyl]-4-[7-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; N-[1-(methoxymethyl)cyclobutyl]-4-[7-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; N-[(1S)-1-(methoxymethyl)-2-methylpropyl]-4-[7-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-b][1,2,4]triazin-2 -yl]benzamide; N-[4-(methoxymethyl)tetrahydro-2H-pyran-4-yl]-4-[7-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-b][1,2,4]triazin- 2-yl]benzamide; 4-[7-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-N-1,3-thiazol-2-ylbenzamide; N-pyrimidin-4-yl-4-[7-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; N-[4-(methoxymethyl)tetrahydro-2H-pyran-4-yl]-4-[7-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-b][1,2,4]triazin- 2-yl]benzamide; N-cyclopropyl-2-fluoro-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; 2-fluoro-N-[1-(methoxymethyl)cyclopropyl]-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; 2-fluoro-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-N-(tetrahydro-2H-pyran-4-yl )benzamide; (3R)-1-{2-fluoro-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzoyl}pyrrolidin-3- ola; 2-fluoro-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; 2-fluoro-N-(trans-4-hydroxycyclohexyl)-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; 6-{2-[3-fluoro-4-(1H-imidazol-1-yl)phenyl]imidazo[1,2-b][1,2,4]triazin-7-ylmethyl}quinoline; 3-{2-fluoro-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]phenyl}-1,3-oxazolidin-2 - her N-(1S)-2,2-dimethyl-1-[(methylamino)carbonyl]propyl-2-fluoro-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2 ,4]triazin-2-yl]benzamide; N-(1S)-1-[(dimethylamino)carbonyl]-2,2-dimethylpropyl-2-fluoro-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b] [1,2, 4]triazin-2-yl]benzamide; N-[(1S)-1-(azetidin-1-ylcarbonyl)-2,2-dimethylpropyl]-2-fluoro-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1 ,2,4]triazin-2-yl]benzamide; N-{(1S)-1-[(dimethylamino)carbonyl]-3-methylbutyl-2-fluoro-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4 ]triazin-2-yl]benzamide; 2-fluoro-N-{(1R)-3-methyl-1-[(methylamino)carbonyl]butyl}-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2 ,4]triazin-2-yl]benzamide; N-{(1R)-1-[(dimethylamino)carbonyl]-3-methylbutyl}-2-fluoro-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2, 4]triazin-2-yl]benzamide; N-[(1R)-1-(azetidin-1-ylcarbonyl)-3-methylbutyl]-2-fluoro-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2 ,4]triazin-2-yl]benzamide; 3-{4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-1H-pyrazol-1-yl}propanenitrile; 4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-1H-pyrazol-1-ylacetonitrile; 2-{4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-1H-pyrazol-1-yl}acetamide; methyl-4-{4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-1H-pyrazol-1-yl}piperidin-1 -carboxylate; 2-fluoro-N-[(1S,2S)-2-hydroxycyclopentyl]-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl ]benzamide; 2-fluoro-N-(2-hydroxyethyl)-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; 2-fluoro-N-[1-(methoxymethyl)cyclobutyl]-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; 2-fluoro-N-[4-(methoxymethyl)tetrahydro-2H-pyran-4-yl]-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4] triazin-2-yl]benzamide; N-(cyclopropylmethyl)-2-fluoro-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; 2-fluoro-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-N-(tetrahydro-2H-pyran-4-ylmethyl) )benzamide; N-[2-(dimethylamino)ethyl]-2-fluoro-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; 2-fluoro-N-(2-piperidin-1-ylethyl)-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide ; 2-fluoro-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin- 2-yl]benzamide; 2-fluoro-N-(pyridin-2-ylmethyl)-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; 2-fluoro-N-(pyridin-3-ylmethyl)-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; 2-fluoro-N-(pyridin-4-ylmethyl)-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; 2-fluoro-N-(2-pyridin-2-ylethyl)-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b] [1,2,4]triazin-2-yl]benzamide ; 2-fluoro-N-(1-pyridin-3-ylethyl)-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide ; 2-fluoro-N-(1-pyridin-4-ylethyl)-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide ; 2-fluoro-N-[(1S)-1-(hydroxymethyl)-2,2-dimethylpropyl]-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4 ]triazin-2-yl]benzamide; 2-fluoro-N-[1-(hydroxymethyl)cyclopentyl]-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; 2-fluoro-N-(2-methoxy-1-methylethyl)-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; 6-{1-[6-(3-fluoro-4-[(3S)-3-fluoropyrrolidin-1-yl]carbonylphenyl)imidazo[1,2-a]pyrimidin-3-yl]cyclopropyl}quinoline; 2-fluoro-N-(pyridin-2-ylmethyl)-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; 2-fluoro-N-(1-pyridin-2-ylcyclopropyl)-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; 2-fluoro-N-(1-pyridin-2-ylpyrrolidin-3-yl)-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; 2-Fluoro-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]-N-[(3R)-tetrahydrofuran-3-yl]benzamide; 2-fluoro-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]-N-(tetrahydrofuran-2-ylmethyl)benzamide; N-cyclopropyl-2-fluoro-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; 2-fluoro-N-[(1S)-1-(methoxymethyl)-2-methylpropyl]-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl] benzamide; 2-fluoro-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; 2-fluoro-N-methyl-N-2-[methyl(pyridin-2-yl)amino]ethyl-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6 -yl]benzamide; 2-chloro-N-methyl-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; 2-Chloro-N-cyclopropyl-4[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; 2-chloro-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]-N-(tetrahydrofuran-3-yl)benzamide; 2-chloro-N-(1-pyridin-2-ylethyl)-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; 6-(1-{6-[4-(Azetidin-1-ylcarbonyl)-3-chlorophenyl]imidazo[1,2-a]pyrimidin-3-yl}cyclopropyl)quinoline; 2-chloro-N-(1-pyridin-2-ylpyrrolidin-3-yl)-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; 2-chloro-N-[1-methyl-2-(pyridin-2-yloxy)ethyl]-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl ]benzamide; 2-chloro-N-(1S)-1-[(dimethylamino)carbonyl]-2-methylpropyl-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl ]benzamide; 2-cyclopropyl-5-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]isoindolin-1-one; 2-ethyl-5-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]isoindolin-1-one; 2-(2-methoxy-1-methylethyl)-S-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]isoindolin-1-one; 2-(pyridin-2-ylmethyl)-5-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]isoindolin-1-one; 2-methyl-5-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]isoindolin-1-one; N-ethyl-1-{4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]phenyl}cyclopropanecarboxamide; N-(1-pyridin-2-ylethyl)-1-{4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]phenyl}cyclopropanecarboxamide; N-[1-methyl-2-(pyridin-2-yloxy)ethyl]-1-{4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl] phenyl}cyclopropanecarboxamide; 2-{2-fluoro-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]phenyl}-2-hydroxy-N-methylacetamide; 2-{2-fluoro-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]phenyl}-2-hydroxy-N,N-dimethylacetamide; N-(3-[2-(4-bromo-3-fluorophenyl)imidazo[1,2-b][1,2,4]triazin-7-yl]methylphenyl)-N'-ethylurea; 2-(2,3-dichlorophenyl)-7-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-b][1,2,4]triazin-3-amine; 2,3-difluoro-N-methyl-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; 6-difluoro-N-methyl-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzamide; 2-fluoro-N-methyl-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]benzenesulfonamide; N,N-dimethyl-2-{3-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl]-1H-pyrazol-1-yl}acetamide; N-[(1S)-1-(azetidin-1-ylcarbonyl)-2,2-dimethylpropyl]-2-fluoro-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a] pyrimidin-6-yl]benzamide; N-[2-(dimethylamino)-1-methyl-2-oxoethyl]-2-fluoro-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6-yl] benzamide; N-(2-azetidin-1-yl-1-methyl-2-oxoethyl)-2-fluoro-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2-a]pyrimidin-6- 1]benzamide; 2-fluoro-N-2-[(3R)-3-methoxypyrrolidin-1-yl]-1-methyl-2-oxoethyl-4-[3-(1-quinolin-6-ylcyclopropyl)imidazo[1,2- a]pyrimidin-6-yl]benzamide; 2-fluoro-N-[(1-hydroxycyclopropyl)methyl]-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide; methyl-4-(cyanomethyl)-4-{4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-1H-pyrazol-1 -yl}piperidin-1-carboxylate; ethyl-4-(cyanomethyl)-4-{4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-1H-pyrazol-1 -yl}piperidin-1-carboxylate; (1-Acetyl-4-{4-[7-(quinolin-6-ylmetil)imidazo[1,2-b] [1,2,4]triazin-2-yl]-1H-pyrazol-1-yl} piperidin-4-yl)acetonitrile, or their pharmaceutically acceptable salts. 51. The compound according to claim 1, characterized in that 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2- yl]benzamide or a pharmaceutically acceptable salt thereof. 52. Composition, characterized in that it contains the compound of any claim from 1 to 51 or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier. 53. Composition, characterized in that it contains the compound according to claim 51 or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier. 54. A method of inhibiting receptor or non-receptor tyrosine kinase activity ex vivo, characterized in that it includes bringing said kinase into contact with a compound from any of claims 1 to 51 or a pharmaceutically acceptable salt thereof. 55. The method according to claim 54, characterized in that said kinase belongs to the Met, PDGFR, HER, FLK, Src, Abl or Jak subfamily. 56. The method according to claim 54, characterized in that said kinase is c-Met, Ron, PDGFR beta, c-kit, EGFR, HER2, KDR, flt-3, Src, Abl, Jak1, Jak2 or Jak 3 kinase. 57. The method according to claim 54, characterized in that said kinase is c-Met. 58. A method of inhibiting the HGF/c-Met kinase signaling pathway in a cell ex vivo, characterized in that it comprises contacting said cell with the compound of any one of claims 1 to 51 or a pharmaceutically acceptable salt thereof. 59. A method of inhibiting the proliferative activity of a cell ex vivo, characterized in that it includes bringing said cell into contact with the compound of any one of claims 1 to 51 or a pharmaceutically acceptable salt thereof. 60. The compound according to any claim from 1 to 51 or its pharmaceutically acceptable salt, indicated to be used in the inhibition of tumor growth in patients. 61. The compound according to any claim from 1 to 51 or its pharmaceutically acceptable salt, characterized in that they are used in the inhibition of tumor metastasis in patients. 62. The compound according to any claim from 1 to 51 or its pharmaceutically acceptable salt, indicated to be used in the treatment of a disease in a patient, where said disease is associated with improper regulation of the HGF/c-MET signaling pathway. 63. The compound or its pharmaceutically acceptable salt according to claim 62, characterized by the fact that they are used in the treatment of diseases wherein the specified disease is cancer, atherosclerosis, pulmonary fibrosis, renal fibrosis and regeneration, liver disease, allergic disorder, inflammatory disease, autoimmune disorder, cerebrovascular disease, cardiovascular disease or a condition related to organ transplantation. 64. The compound according to any claim from 1 to 51 or its pharmaceutically acceptable salt, indicated to be used in the treatment of cancer in a patient. 65. The compound or its pharmaceutically acceptable salt according to claim 64, characterized in that it is used in the treatment of cancer, wherein said cancer is carcinoma, musculoskeletal sarcoma, soft tissue sarcoma or hematopoietic malignancy. 66. The compound or its pharmaceutically acceptable salt according to claim 64, characterized in that they are used in the treatment of cancer, wherein said cancer is bladder cancer, breast cancer, cervical cancer, cholangiocarcinoma, colon cancer, esophageal cancer, stomach cancer, head cancer and neck, kidney cancer, liver cancer, lung cancer, nasopharyngeal cancer, ovarian cancer, pancreatic cancer, prostate cancer, thyroid cancer, osteosarcoma, synovial sarcoma, rhabdomyosarcoma, MFH/fibrosarcoma, leiomyosarcoma, Kaposi's sarcoma, multiple myeloma, lymphoma, leukemia adult T cells, acute myelogenous leukemia, chronic myeloid leukemia, glioblastoma, astrocytoma, melanoma, mesothelioma or Wilms tumor. 1